Jaap Verweij
Erasmus University Rotterdam
569 Papers
8.1K Citations
Jaap Verweij is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Chemotherapy. The author has an hindex of 94, co-authored 567 publications.
Chat about Author
Papers
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer,Isabelle Ray-Coquard,Zsuzsa Papai,Axel Le Cesne,Michelle Scurr,Patrick Schöffski,F. Collin,Lini Pandite,Sandrine Marreaud,Annick De Brauwer,Martine Van Glabbeke,Jaap Verweij,Jean-Yves Blay +12 more
TL;DR: Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patientswith leiomyosarcoma, synovial sarcomas, and other STS types.
682
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Armando Santoro,Thomas Tursz,Henning T. Mouridsen,Jaap Verweij,William P. Steward,Riet Somers,J. Buesa,Paolo G. Casali,David Spooner,E.M. Rankin +9 more
TL;DR: In advanced soft tissue sarcoma patients for whom significant tumor volume reduction may be an important end point of a chemotherapy regimen, single-agent doxorubicin is still the standard chemotherapy against which more intensive or new drug treatments should be compared.
533
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Andrea Ardizzoni,Heine H. Hansen,Per Dombernowsky,Teresa Gamucci,Shoshana Kaplan,Pieter E. Postmus,Giuseppe Giaccone,Brigitte Schaefer,Jantien Wanders,Jaap Verweij +9 more
TL;DR: In this paper, the authors assessed activity and toxicity of topotecan in previously treated small-cell lung cancer (SCLC) patients with measurable SCLC, progressive after one first-line regimen.
451
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Jaap Verweij,A. van Oosterom,Jean-Yves Blay,Ian Judson,Sjoerd Rodenhuis,W.T.A. van der Graaf,John Radford,A. Le Cesne,Pcw Hogendoorn,E. Donato Di Paola,M. Brown,O.S. Nielsen +11 more
TL;DR: In this article, the authors evaluated the antitumour response and time to progression (TTP) of patients treated with imatinib mesylate (Glivec®, Gleevec™, formerly STI-571) who had advanced and/or metastatic gastrointestinal stroma tumours (GIST) or other soft tissue sarcomas (STS).
394
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
M. de Boer-Dennert,R. de Wit,Paul I.M. Schmitz,J. Djontono,V. van Beurden,G. Stoter,Jaap Verweij +6 more
TL;DR: The purpose of this study was to evaluate the impact of 5HT3 antagonists on patient perceptions of the side-effects of chemotherapy and found that hair loss appeared to be more distressing to women than nausea and vomiting, but, in other aspects, gender, age and marital status did not influence the ranking of the three most distressing side- effects.
391